Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
Verified date | March 2019 |
Source | Helix BioPharma Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in patients with non-squamous non-small cell lung cancer when given as a monotherapy.
Status | Completed |
Enrollment | 76 |
Est. completion date | December 20, 2017 |
Est. primary completion date | August 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Main Inclusion Criteria: Patients will be entered in the study only if they meet all of the following criteria: 1. Male or female aged = 18 years old 2. Have histologically confirmed non-squamous NSCLC that are: 1. Chemo naïve Stage IIIb or IV non-squamous NSCLC who are not candidates for chemotherapy or radiotherapy, or who refused standard therapy 2. Refractory Stage IIIb or IV non-squamous NSCLC. (Staging of non-squamous NSCLC must be assessed according to TNM, 7th edition and based on computed tomography (CT) scan.) 3. Have at least a single measurable lesion in accordance with the RECIST v1.1 criteria. 4. Eastern Cooperative Oncology Group (ECOG) performance status: 0-2 5. Have a life expectancy of = 3 months 6. Have adequate bone marrow, renal and liver function Main Exclusion Criteria: 1. Are pregnant or nursing mother 2. Have a prior history of other malignancies with the exception of non melanoma skin cancer 3. Have known history of central nervous system (CNS) metastatic disease (previously treated or untreated) 4. Show evidence of active infection 5. Have received treatment in another clinical study within the 30 days before commencing study drug or have not recovered from side effects of a study drug, except for alopecia 6. Have a serious uncontrolled medical condition 7. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or hepatitis C positive 8. Sustained QTc (QT interval corrected for heart rate) with Fridericia's correction > 450 ms at screening, or a history of additional risk factors for Torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome) 9. Pre-existing peripheral neuropathy = CTC Grade 2 10. Have dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent or compliance with the requirements of the protocol 11. Are receiving chemotherapy during the 30 days before study treatment start; are receiving radiotherapy, targeted therapy, hormonal therapy, immunotherapy, major surgery or other study drugs during the 4 weeks before study treatment start, or have not recovered from all treatment related toxicities to Grade = 1, except for alopecia. (Radiotherapy is allowed for the symptomatic treatment of bone metastases.) 12. Are taking systemic steroids (other than inhalers or topical steroids) or other medication to suppress the immune system 13. Are participating (or planning to participate) in any other clinical trial during this study. |
Country | Name | City | State |
---|---|---|---|
Poland | Mazovian Center of Pulmonary Diseases and Tuberculosis | Otwock | |
Poland | Med. Polonia Hospital Poznan | Poznan | |
Poland | Institute of Tuberculosis and Lung Diseases | Warsaw | |
Poland | Military Medical Institute | Warsaw | |
Poland | The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology | Warsaw |
Lead Sponsor | Collaborator |
---|---|
Helix BioPharma Corporation | Pharm-Olam International |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Maximum observed plasma concentration (Cmax) of L-DOS47 at each dose level | Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patient dosed with L-DOS47. | Up to 12 weeks | |
Other | Time to maximum observed plasma concentration (Tmax) of L-DOS47 at each dose level | Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patient dosed with L-DOS47. | Up to 12 weeks | |
Other | Area under the concentration (AUC) vs time curve of L-DOS47 at each dose level | Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patient dosed with L-DOS47. | Up to 12 weeks | |
Other | Terminal elimination half-life of L-DOS47 at each dose level | Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patient dosed with L-DOS47. | Up to 12 weeks | |
Primary | The incidence and severity of drug-related adverse events as a measure of safety and tolerability of L-DOS47 | Assessed during the AE reporting period starts on Cycle 1 Day 1 up to the last study visit. | Up to 12 weeks | |
Secondary | L-DOS47 related toxicity during the first 2 hours after infusion | Assessed by the incidence and severity of AEs and SAEs and changes in vital signs | During the first 2 hours after infusion | |
Secondary | The incidence and severity of all reported adverse events and serious adverse events | Assessed during the AE reporting period starts on Cycle 1 Day 1 up to the last study visit. | Participants will be followed for 12 weeks and the 30 day follow-up period | |
Secondary | Changes from baseline for additional safety parameters (clinical laboratory assessments, vital signs, weight, oxygen requirement and 12-lead ECG) | Safety parameters include clinical laboratory assessments, vital signs, weight, oxygen requirement and 12-lead ECG | Up to 12 weeks | |
Secondary | The evaluation of anti-L-DOS47 antibody over time | Serum samples will be collected and analyzed from all patients dosed with L-DOS47. | Up to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |